The sequential use of abiraterone and enzalutamide (MDV3100) in castrate resistant prostate cancer patients: Experience from Birmingham, United Kingdom.

被引：0
|
作者：
Stevenson, Robert
Ford, Daniel
Zarkar, Anjali M.
Glaholm, John
Porfiri, Emilio
Tew, Alice
El-Modir, Ahmed
James, Nicholas David
机构：
[1] Univ Hosp Birmingham, Birmingham, W Midlands, England
[2] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
[3] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England
[4] Univ Birmingham, Sch Canc Sci, Birmingham, W Midlands, England
[5] Univ Birmingham, Birmingham, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16048
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide
    Woon, Dixon T. S.
    Finelli, Antonio
    Cheung, Douglas C.
    Martin, Lisa J.
    Alibhai, Shabbir
    Wallis, Christopher J. D.
    Diong, Christina
    Saskin, Refik
    Kulkarni, Girish
    Fleshner, Neil
    UROLOGY, 2021, 153 : 147 - 154
  • [42] A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide
    Tsao, Phoebe A.
    Caram, Megan E. V.
    UROLOGY, 2021, 153 : 154 - 154
  • [43] CIRCULATING TUMOR CELLS (CTC) AND PROSTATE-SPECIFIC ANTIGEN (PSA) AS RESPONSE INDICATOR BIOMARKERS IN CHEMOTHERAPY-NAIVE PATIENTS WITH PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER (CRPC) TREATED WITH MDV3100
    Hirmand, M.
    Scher, H. I.
    Beer, T.
    Higano, C. S.
    Taplin, M.
    Efstathiou, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 277 - 277
  • [44] Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer
    Mori, Keiichiro
    Kimura, Takahiro
    Onuma, Hajime
    Kimura, Shoji
    Yamamoto, Toshihiro
    Sasaki, Hiroshi
    Miki, Jun
    Miki, Kenta
    Egawa, Shin
    PROSTATE, 2017, 77 (10): : 1144 - 1150
  • [45] A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide REPLY
    Fleshner, Neil
    UROLOGY, 2021, 153 : 155 - 155
  • [46] Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience
    Valeriani, Maurizio
    Marinelli, Luca
    Macrini, Serena
    Reverberi, Chiara
    Aschelter, Anna Maria
    De Sanctis, Vitaliana
    Marchetti, Paolo
    Tronnolone, Lidia
    Osti, Mattia Falchetto
    RADIATION ONCOLOGY, 2019, 14 (01)
  • [47] Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience
    Maurizio Valeriani
    Luca Marinelli
    Serena Macrini
    Chiara Reverberi
    Anna Maria Aschelter
    Vitaliana De Sanctis
    Paolo Marchetti
    Lidia Tronnolone
    Mattia Falchetto Osti
    Radiation Oncology, 14
  • [48] Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
    Massard, Christophe
    Retz, Margitta
    Hammerer, Peter
    Quevedo, Fernando
    Fong, Peter C. C.
    Berry, William R.
    Gurney, Howard
    Piulats, Josep M.
    Joshua, Anthony
    Linch, Mark David
    Kolinsky, Michael
    Romano, Emanuela
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Augustin, Marinela
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [49] A Phase 2 trial of sipuleucel-T in combination with concurrent or sequential abiraterone acetate (AA) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Small, E.
    Lance, R.
    Gardner, T. A.
    Karsh, L. I.
    Stubbs, A.
    McCoy, C.
    DeVries, T.
    Redfern, C. H.
    Shore, N. D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S682 - S683
  • [50] NUMBER NEEDED TO TREAT AND ASSOCIATED INCREMENTAL COSTS OF TREATMENT WITH ENZALUTAMIDE VERSUS ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN SPAIN AND THE UNITED KINGDOM
    Duran, A.
    Watt, M.
    Flanders, S.
    Schultz, N. M.
    VALUE IN HEALTH, 2017, 20 (05) : A107 - A107
12345